Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

Patent metadata

Field	Value
Publication number	US-11608308-B2
Application number	US-202017110236-A
Country	US
Kind code	B2
Filing date	Dec 2, 2020
Priority date	Jun 7, 2016
Publication date	Mar 21, 2023
Grant date	Mar 21, 2023

Abstract

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.

First claim

What is claimed is:

1. A method of reducing epileptiform activity in the brain of a subject and/or treating in said subject one or more conditions selected from the group consisting of Alzheimer's disease, epilepsy, Parkinson's disease, heart failure, traumatic brain injury, stroke, hemorrhagic shock, acute lung injury after fluid resuscitation, acute kidney injury, myocardial infarction, myocardial ischemia, diabetes, glioblastoma multiforme, diabetic neuropathy, prostate cancer, amyotrophic lateral sclerosis, Huntington's disease, cutaneous T cell lymphoma, multiple myeloma, peripheral T cell lymphoma, HIV, and Niemann-Pick Type C disease said method comprising:
administering to said subject, a therapeutically effective amount of a compound of the Formula:

or a compound of Formula II:

or salts, solvates or hydrates thereof, wherein:
R 4 is H or C(1-6) alkyl or substituted alkyl; and
R 5 and R 6 are independently unsubstituted or substituted straight chain C(4-30) alky.

2. The method of claim 1 , wherein the therapeutically effective amount is sufficient to reduce epileptiform activity in the brain of the subject.

3. The method of claim 2 , wherein said method comprises a method of reducing epileptiform activity in the brain of the subject.

4. The method of claim 1 , wherein said compound comprises a compound of Formula II.

5. The method of claim 4 , wherein R4 is an unsubstituted C(1-6) alkyl.

6. The method of claim 5 , wherein R4 is methyl.

7. The method of claim 4 , wherein R5 and R6 are independently unsubstituted C(6-18) alkyl.

8. The method of claim 4 , wherein R 5 and R 6 are independently unsubstituted C6 alkyl or independently unsubstituted C8 alkyl.

9. The method of claim 4 , wherein said compound is compound of Formula IIa:

10. The method of claim 4 , wherein said compound is a compound of Formula IIb:

11. The method of claim 4 , wherein said compound is compound having the formula:

12. The method of claim 1 , wherein said compound is compound having the formula:

13. The method of claim 1 , wherein said compound is compound having the formula:

14. The method of claim 1 , wherein said compound is compound having the formula:

15. The method of claim 1 , wherein said compound is compound having the formula:

16. The method of claim 1 , wherein said compound is administered as an oral preparation.

17. The method of claim 16 , wherein said oral preparation comprises a preservative and/or a flavoring agent.

18. The method of claim 17 , wherein said oral preparation comprises water.

19. The method of claim 18 , wherein said oral preparation comprises a syrup or an elixir.

20. The method of claim 18 , wherein said oral preparation comprises a suspension.

21. The method of claim 17 , wherein said oral preparation comprises a binder.

22. The method of claim 21 , wherein said oral preparation comprises a binder selected from the group consisting of cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, poly(ethylene glycol), sucrose, and starch.

23. The method of claim 17 , wherein said oral preparation comprises a flavoring agent.

24. The method of claim 23 , wherein said oral preparation comprises a flavoring agent selected from the group consisting of citric acid, menthol, glycine, and orange powder.

25. The method of claim 17 , wherein said oral preparation comprises a preservative.

26. The method of claim 25 , wherein said oral preparation comprises a preservative selected from the group consisting of sodium benzoate, sodium bisulfate, methylparaben, and propylparaben.

27. The method of claim 1 , wherein compound is administered as a food supplemented with said compound(s).

28. The method of claim 27 , wherein said food comprises one or more additional components of a ketogenic diet.

Assignees

• The J David Gladstone Inst
• Univ California
• Ithaca College

Inventors

• Verdin Eric
• Ulrich Scott Michael
• Newman John C

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• G02B1/04

  made of organic materials, e.g. plastics (G02B1/08 takes precedence) · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P19/06

  Antigout agents, e.g. antihyperuricemic or uricosuric agents · CPC title